Wales is a self-governing country of the UK and the Welsh Government is the devolved Government for Wales. The Welsh Government’s decision-making powers within a small and joined-up country mean we can act fast. They also mean we are responsible for our own economic development, so you won’t find a more pro-business Government anywhere. Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. Wales means business.
Van Heron Labs
. | Van Heron Labs (VHL) The Cellular Intelligence Layer for Life Sciences Booth #1611 | vanheronlabs.com | contact@vanheronlabs.com — Van Heron Labs is transforming how biological processes are designed, optimized, and scaled. VHL has built the most powerful cellular intelligence engine ever created — the only end-to-end, multi-omic digital twin platform designed exclusively for cellular optimization. At the core of VHL’s platform is a proprietary system that decodes complete cellular biology — gene expression, metabolism, stress responses, and biomolecular needs across 17 molecular categories spanning thousands of compounds — and translates that data into a real-time biological digital twin. VHL identifies and predicts the impact of every critical biomolecule: metabolites, ions, trace metals, minerals, cofactors, growth factors, cytokines, ECM components, and more. The result: VHL customers see breakthrough improvements in titer, viability, potency, and manufacturability — faster and at a fraction of the cost of traditional R&D. Proven across cell therapy, biologics, precision fermentation, and more: T cell therapies (CD4/CD8, TIL, Treg): 80% improved viability, 40% increase in activation, FOXP3 stability for greater potency — saving $25K–$60K per batch iPSC programs: ~25 critical ingredients identified, many absent from any commercial media — 10X cheaper than internal R&D, 5 months faster to clinic MSC programs: ~30 critical ingredients identified, resolving stress pathways and improving scale-up reliability — unlocking $25–80M in potential new media product revenue HEK / bioprocessing: 40–200% proliferation improvement, 900% cell density gains with process optimization, 360% higher protein titer Microbial (E. coli, B. subtilis, P. aeruginosa): 200–400% proliferation increases, 200–360% higher titer, fully defined bioreactor media. How you can work with VHL: VHL offers four flexible engagement models — Analytics Only (1-week turnaround), Process Development Recommendations (1–2 weeks), Co-Development (3–10 weeks), and Strategic Partnerships for long-term innovation. All engagements begin with RNA-Seq or proteomics data and deliver interactive, publication-quality multi-omics reports, biological digital twins, and actionable recommendations your team can execute immediately. Backed by NVIDIA, Microsoft, and AWS, and trusted by dozens of life science companies, large and small. Who we’re looking to meet at BIO 2026: VHL is actively seeking strategic partnerships with CDMOs, CROs, reagent and culture media manufacturers, and asset-focused companies looking to improve manufacturing performance, reduce R&D burden, develop proprietary formulations, and unlock new revenue streams through the power of cellular intelligence. Want to connect before San Diego? Schedule a meeting or platform demo with CEO & Founder Rebecca Vaught, Ph.D. at calendly.com/rvaught-vanheronlabs/30min — or stop by Booth #1611 and meet us in person. We’d love to show you what cellular intelligence can do for your program.
Sygnature Discovery
At Sygnature Discovery, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible. We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment. Over the past 20 years, we’ve earned a track record of real impact: 60+ advanced candidates, 200+ patents filed, 200+ active projects. Over 90% of our customers choose to stay with us – from biotechs racing to clinic to pharma companies that need specialised expertise for targeted challenges.
SWISS Pavilion
Switzerland at BIO 2025: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2025 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2025. Join us in shaping the future of global health – the Swiss way. | Switzerland at BIO 2026: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2026 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2026. Join us in shaping the future of global health – the Swiss way. | Swissenviro was founded in 2015 by Urs Heutschi. It is a small, privately-owned company and the organizer of the SWISS Pavilion at international trade fairs for environmental technologies. With more than 20 years of experience, the international fair work is our area of expertise and forms the core of our work. The aim is to support export-orientated Swiss Cleantech SME to find buyers and business partners in international markets by encouraging international networking and direct B2B contacts on trade fairs and other events. By participation in a Joint Swiss Booth, the “SWISS Pavillon”, we are bringing together Swiss SMEs with professional trade visitors – potential future buyers, partners or suppliers. If desired, we gladly accompany and support the SME further on its business project resulting from this first customer contact. We closely work together with relevant Swiss environmental associations such as Cleantech Alps, VSA and Energie-Cluster. For our SWISS Pavilions we are supported by the MPK from “Switzerland Global Enterprise” (S-GE) and the “Swiss Federal Office for the Environment” (FOEN).
Solvias
Solvias helps innovative companies advance their path to commercialization with CMC analytical solutions powered by deep scientific expertise and a relentless focus on our customers’ success. With years of expertise in cell & gene therapy, biologics and small molecules, and an offering that spans the drug development process, our talented subject matter experts have the know-how, creativity, and tenacity to solve even the most complex analytical challenges.
Shanghai Taichu Biotechnology Co., Ltd.
Taichu group was founded in 2020, providing contract research, development and manufacturing services to pharmaceutical and biotech companies. Our service platforms include early discovery and design of complex antibodies such as multispecific antibodies, nanobodies, fusion proteins etc. Our GLP- and AAALAC- certified animal facility provides preclinical studies (PK/PD), safety evaluation (Toxicology) for a various modality of drug candidates, such as small molecules, biologics, ADC, CGT products, and RNAi, ASO, mRNA molecules. For development and manufacturing of complex antibodies, our CDMO (Tarlead) has experienced teams, well-established laboratories and facility for process development, drug substance production and drug product manufacturing, ready to meet your needs and timelines. | Taichu Group is a biotechology enterprise with a core advantage in “CRO+CDMO integrated services”, providing end-to-end solutions for global innovative drug development from early discovery through preclinical research. Headquartered in Shanghai’s Lingang Special Area, the Group operates through its subsidiaries: Taichu Bio (Pre-Clinical Research), AceMab Ltd (Antibody Discovery & Design), Tarlead Biologics (Biologics Development & Manufacturing), TJR Bio (Nucleic Acid Drug Process & Manufacturing), and Taichu (Shenzhen) (Innovative Therapeutic Development Advisory). Guided by the philosophy “Advocate of Ethics and Integrity, Quest for Verity”, we streamline R&D workflows and accelerate therapeutic advancement for global partners. Our synergistic service model bridges key gaps between discovery and commercialization, reinforcing our role as a strategic enabler in the biopharmaceutical innovation value chain.
SanaClis CRO
SanaClis CRO – Founded in 2000, SanaClis is a full-service global CRO with strong in-house clinical supply chain, logistics, and sourcing capabilities. We support clinical trials worldwide across the full study lifecycle and can operate as either a full-service or functional service provider, depending on sponsor needs. We have delivered clinical trial projects for sponsors ranging from virtual biotech to top 10 pharmaceutical companies, combining operational rigor with responsive execution and a focus on quality and predictable delivery. SanaClis provides CRO and clinical supply chain services across all therapeutic areas, with coverage across Europe (including the UK), USA (Americas) and Asia. We also bring deep operational experience in Central and Eastern Europe (CEE), supporting strong patient access and reliable site performance. To enable global distribution, SanaClis operates a network of privately owned, GMP- and GDP-certified depots strategically located worldwide. Our facilities support ambient and cold-chain storage, as well as packaging, labeling, and distribution services to protect product integrity throughout the IMP cold chain. CRO Services: Project Management, Clinical Monitoring, Site Management, Regulatory, Medical Writing, Data Management, Biostatistics, Pharmacovigilance, Medical Monitoring, Quality Management, Decentralized Trials. Clinical Supply Chain Services: Storage and Distribution, Secondary Packaging and Labelling, Global Strategic Sourcing, Qualified Person Services, Customs and Brokerage, SIMS – Inventory Management, Direct to Patient Services. Please reach out to Matt Delaney, Vice President of Business Development for the Americas region, email: matt.delaney@sanaclis.com or by phone at: 1 805 798-0060. Matt resides in San Diego, Ca.